The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy
about
Clinical Development of the E75 Vaccine in Breast CancerTargeted Therapies in HER2-Positive Breast Cancer - a Systematic ReviewNucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical SensingPotential prognostic, diagnostic and therapeutic markers for human gastric cancerSecond harmonic super-resolution microscopy for quantification of mRNA at single copy sensitivity.Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.The Anti-Cancer Effect of Polyphenols against Breast Cancer and Cancer Stem Cells: Molecular MechanismsMembrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumorsIdentification of putative drug targets for human sperm-egg interaction defect using protein network approach.Glycoengineering of pertuzumab and its impact on the pharmacokinetic/pharmacodynamic properties.Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer.Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage.Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancerTransducin (β)-like 1 X-linked receptor 1 promotes proliferation and tumorigenicity in human breast cancer via activation of beta-catenin signaling.Contralateral risk-reducing mastectomy: review of risk factors and risk-reducing strategies.Identification of valid reference genes for the normalization of RT-qPCR expression studies in human breast cancer cell lines treated with and without transient transfection.Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2- Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study.Immune microenvironment as a factor of breast cancer progression.Promoter methylation of BRCA1 is associated with estrogen, progesterone and human epidermal growth factor receptor-negative tumors and the prognosis of breast cancer: A meta-analysisOcular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical TrialsSingle-cell screening and quantification of transcripts in cancer tissues by second-harmonic generation microscopy.Kruppel-like factor 2 suppresses mammary carcinoma growth by regulating retinoic acid signaling.Intrinsically active variants of Erk oncogenically transform cells and disclose unexpected autophosphorylation capability that is independent of TEY phosphorylationTrastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results.EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma.Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancerState of the art in anti-cancer mAbs.Docetaxel loaded nanostructured lipid carriers functionalized with Trastuzumab (Herceptin) for HER2-positive breast cancer cells.Manganese Superoxide Dismutase Acetylation and Dysregulation, Due to Loss of SIRT3 Activity, Promote a Luminal B-Like Breast Carcinogenic-Permissive Phenotype.Low-volume multiplexed proteolytic activity assay and inhibitor analysis through a pico-injector array.Integration of platinum nanoparticles with a volumetric bar-chart chip for biomarker assaysAnticancer Chemodiversity of Ranunculaceae Medicinal Plants: Molecular Mechanisms and Functions.SERS analysis of serum for detection of early and locally advanced breast cancer.Constructing real-time, wash-free, and reiterative sensors for cell surface proteins using binding-induced dynamic DNA assembly.N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by 89Zr-Trastuzumab and 18F-FDG PET imagingPhysicochemical and biological characterization of a biosimilar trastuzumab.Down-regulation of C35 decreased the cell viability and migration of breast ductal carcinoma cells.Potential Diagnostic and Therapeutic Applications of Oligonucleotide Aptamers in Breast CancerFunctionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields.Pharmacokinetic Comparability of a Biosimilar Trastuzumab Anticipated from Its Physicochemical and Biological Characterization.
P2860
Q26745440-32686F41-6EED-4263-B64B-FC3C75FCF454Q26777733-39B71C99-9BDB-4DEF-AA0E-DE38955BF8C0Q26825644-B2F2B65D-C3E9-4F19-9EF4-028C6B931992Q26866200-2F816BA2-7975-4BF8-9044-3B088FA58118Q27335005-E3CD9762-7C2F-45D3-AECD-90359ADCCA8CQ27853078-80EBF03D-2B7C-4146-ABC8-843D721BBDF3Q28066752-6EDD94FE-3E51-4605-A25B-5BC141D1EBDEQ30278773-F650C95F-77C8-443F-8BB7-ADD32591A4B0Q30658102-801A40B7-403C-4D4F-BA0A-54889376CBE0Q33551688-11ECBF0F-080C-4A5F-8A88-7030EDA632FDQ33557258-6FA50369-054A-4E55-9AEF-AED3091BF6EFQ34243127-626076DC-CBB2-4894-BE9B-F164F9DE437EQ34446385-5D15D2AF-460B-4D42-BC66-EFE19F8032BFQ35000357-E645BE4E-2EFC-4276-AA8B-533C867B934EQ35066801-4C59EB6F-7C23-4279-A735-B87A12FDB6F2Q35548593-1CF6BE2F-3A09-40F5-86B4-7E6BA65A0638Q35675851-18CDF317-378F-4BB2-BD61-35294F372FC2Q35780464-E9818D16-8CA2-448D-8E44-32C6B373E335Q36334551-4DF8AD0E-03AC-4BB8-AE5C-914EF80063ACQ36366709-067B205E-F40B-4D2E-93CC-194B42413B68Q36397934-2D268997-0E5C-4B14-99A1-CF30764DA435Q36546480-AD4C8E8E-1518-4715-A793-4EE5648EE91FQ36685109-0FD2139A-36E1-4B79-BB8D-D58BA220F5DEQ36802271-68AF6242-7608-40CE-AC7E-8EA28E54DB43Q36962490-04BB89CA-5A22-49DF-9850-99A1957EDBC7Q37619731-CBA2568B-9B77-4954-A1BA-F61A3203F250Q37655585-5FA2F6C2-9B34-439E-AAF3-744C328E434BQ38694486-2BEC4657-54B9-46EC-B91A-E21D9B67ECE5Q38900962-3FC1B2CD-BEF4-41E4-890F-87E43C1322D4Q38923909-F170A098-DE89-4DC8-9C0B-CE77CA343E37Q38973439-6B52BF0D-F3AC-405B-9DAE-C2208BD1CAE4Q39305654-35E1D232-2C80-4313-9CFB-D9E69A2F85CCQ40645063-516F81A0-87D9-4CA4-9B73-FAA4D45F7B90Q41042643-FCEA5DAD-9C28-45FF-9DF2-FBC6903416E1Q41347430-F9B2A5E8-3D59-4E5C-9BB5-9D434717444BQ41443472-14F1A549-32BE-42C4-A0C6-197AC7548424Q41577652-BC64623E-A22C-4E0B-A65D-32C150300FD7Q41661268-5CA68490-8B0C-48F3-8CCE-949C2C8D5ED8Q41673094-FC373286-B566-430E-B20C-486BD6FDB8CFQ42000964-1FFCBA3A-66CC-4A92-A2B1-EDB036BD75B9
P2860
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The HER2 Receptor in Breast Ca ...... e, and New Advances in Therapy
@ast
The HER2 Receptor in Breast Ca ...... e, and New Advances in Therapy
@en
The HER2 Receptor in Breast Ca ...... e, and New Advances in Therapy
@en-gb
The HER2 Receptor in Breast Ca ...... e, and New Advances in Therapy
@nl
type
label
The HER2 Receptor in Breast Ca ...... e, and New Advances in Therapy
@ast
The HER2 Receptor in Breast Ca ...... e, and New Advances in Therapy
@en
The HER2 Receptor in Breast Ca ...... e, and New Advances in Therapy
@en-gb
The HER2 Receptor in Breast Ca ...... e, and New Advances in Therapy
@nl
prefLabel
The HER2 Receptor in Breast Ca ...... e, and New Advances in Therapy
@ast
The HER2 Receptor in Breast Ca ...... e, and New Advances in Therapy
@en
The HER2 Receptor in Breast Ca ...... e, and New Advances in Therapy
@en-gb
The HER2 Receptor in Breast Ca ...... e, and New Advances in Therapy
@nl
P2860
P3181
P356
P1476
The HER2 Receptor in Breast Ca ...... e, and New Advances in Therapy
@en
P2093
Ruth O'Regan
Tina Constantine
P2860
P304
P3181
P356
10.1155/2012/743193
P407
P50
P577
2012-01-01T00:00:00Z